CAMP4 Therapeutics Corporation Common Stock

CAMPNASDAQ • USD
ThemeGenomics & Precision Med.›RNA Therapeutics
4.11 USD
↘ 0.19 (4.42%)AT CLOSE (11:59 AM EDT)
3.96
↘ 0.15 (3.65%)
POST MARKET (AS OF 07:59 PM EDT)
Post Market
AS OF 07:59 PM EDT
3.96
↘ 0.15 (3.65%)
🔴Market: CLOSED
Open?$4.24
High?$4.46
Low?$4.00
Prev. Close?$4.30
Volume?69.0K
Avg. Volume?76.8K
VWAP?$4.18
Rel. Volume?0.90x
Bid / Ask
Bid?$3.80 × 11.0K
Ask?$4.03 × 100
Spread?$0.23
Midpoint?$3.92
Valuation & Ratios
Market Cap?213.4M
Shares Out?51.9M
Float?28.8M
Float %?55.5%
P/E Ratio?N/A
P/B Ratio?6.91
EPS?-$1.66
Dividend?0.00%
Ex-Dividend?N/A

Shares of CAMP4 Therapeutics Corporation Common Stock (CAMP) are trading at $4.11. The stock presents a bearish profile across the board: technical indicators signal "Strong Sell" and our fundamental models agree with a "Sell" rating. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, negative Return on Equity and a bullish Golden Cross on the moving averages. On the valuation front, CAMP trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. The company focuses on genetic diseases of the central nervous system and liver. Its pipeline products include CMP-CPS-001 and CMP-SYNGAP. The company operates as a single operating segment, R&D, which engages in the development of a new class of RNA-based therapeutics to treat a broad range of genetic diseases.
Themes
Healthcare - Genomics & Precision Medicine›RNA TherapeuticsBiotech - Drug Development›Rare Disease Therapeutics
Employees
48
Market Cap
223.3M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.camp4tx.com
Listed
2024-10-11
Address
ONE KENDALL SQUARE
CAMBRIDGE, MA 02139
Phone: 617-651-8867
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
12
Z-Score?
0
Momentum?
50
Short Sent.?
68
Piotroski F-Score?2/9Weak
Altman Z-Score?-3.05Distress
Confidence?51%Low
Full Fundamental Analysis →
Short InterestModerate
Short % of Float?1.12%Low
Short Interest?322.4K
Days to Cover?3.5
Free Float28.8M
Avg Daily Volume91.7K
Settlement Date2026-05-15
Financial Health
Current Ratio?6.10Strong
Quick Ratio?6.10Strong
Cash Ratio?5.97Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
58/100
P/E?
N/A▾
P/B?
Peers
100
S&P
27
6.91FAIR▾
P/S?
Peers
100
S&P
3
54.25HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-2.3CHEAP▾
EV/Sales?
Peers
100
S&P
3
29.03HIGH▾
Returns & Efficiency
ROE?
S&P
3
-279.3%WEAK▾
ROA?
S&P
3
-81.8%WEAK▾
Cash Flow & Enterprise
FCF?$-26248000
Enterprise Value?$114.2M
Fundamentals ratios updated end of day
MarketsMoversWatchlist